RSS   Newsletter   Contact   Advertise with us

Adicet Bio appoints Elizabeth Read as CTO

Staff Writer | Menlo Park, Ca., USA | May 3, 2018
Elizabeth ReadAdicet Bio, a biopharmaceutical company, announced that it has appointed Elizabeth Read as its chief technology officer.
Prior to Adicet, Dr. Read served as SVP, Product Development at Medeor Therapeutics where she led CMC development and tech transfer for phase 2/3 manufacturing of the company's first two product candidates.

Dr. Read's previous roles have included Chief Medical Officer at StemCyte, Head of Product Development at Fate Therapeutics, and Medical Director for Blood and Tissue Services at the American Red Cross.

Dr. Read's focus on cell and gene therapy began at the National Institutes of Health where she served as Section Head and Medical Director of the Clinical Center's cell therapy core facility from 1995 – 2006.

She received her Bachelor of Arts, cum laude from Bryn Mawr College and medical degree from the State University of New York at Buffalo.

She has authored 99 scientific publications and serves on a Biologics & Biotechnology expert committee at the US Pharmacopoeia.